Abstract
The problem of optimal dosage is studied for the administration of ddCyd using erythrocytes as carriers and bioreactors. The volume of erythrocytes and the initial amount of drug to be loaded have to be determined in such a way that the duration of the therapeutic effect is maximized without exceeding the toxic threshold. It is found that the optimal control is unique and it is at the upper vertex of the set of the admissible controls. A more general case is also briefly discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literature
Magnani, M., M. Bianchi, L. Rossi and V. Stocchi. 1989a. Human red blood cells as bioreactors for the release of 2′,3′-dideoxycytidine, an inhibitor of HIV infectivity.Biochem. Biophys. Res. Commun. 164, 446–452.
Magnani, M., M. Bianchi, L. Rossi and V. Stocchi. 1989b. 2′,3′-Dideoxycytidine permeation of the human erythrocytes membrane.Biochem. Int. 19, 227–234.
Mitsuya, H. and S. Broder. 1986. Inhibition of thein vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleoside.Proc. natn. Acad. Sci. U.S.A. 83, 1911–1915.
Solimano, F., G. I. Bischi, M. Bianchi, L. Rossi and M. Magnani. 1990. A nonlinear three-compartment model for the administration of 2′,3′-dideoxycytidine by using red blood cells as bioreactors.Bull. math. Biol. 52, 785–796.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Beretta, E., Solimano, F. An optimal time control problem for the administration of 2′,3′-dideoxycytidine by using red blood cells as bioreactors. Bltn Mathcal Biology 55, 715–730 (1993). https://doi.org/10.1007/BF02460670
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02460670